FDA Center for Drug Evaluation & Research Issues Warning Letter to Shenzhen Benliju Biotech
November 18, 2026
November 18, 2026
WASHINGTON, Nov. 18 (TNSdock) -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Shenzhen Benliju Biotech Co., Ltd. from its Center for Drug Evaluation and Research:
* * *
Recipient: Mr. Xiaojun Xu, General Manager, Shenzhen Benliju Biotech Co., Ltd., Factory Building 303, Qihong Pinshun Industrial Park, 105 Pinshun Road, Guixiang Community, Guanlan Street, Shenzhen Shi Guangdong Sheng, 518000, China
* * *
Recipient: Mr. Xiaojun Xu, General Manager, Shenzhen Benliju Biotech Co., Ltd., Factory Building 303, Qihong Pinshun Industrial Park, 105 Pinshun Road, Guixiang Community, Guanlan Street, Shenzhen Shi Guangdong Sheng, 518000, China
